Reversing the risk factor paradox: Is daily nocturnal hemodialysis the solution?

Seminars in Dialysis

Volumn 20, Issue 6, 2007, Pages 539-543

  Pauly, Robert P ^a   Chan, Christopher T ^a,b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANEMIA; CALCINOSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; ENDOTHELIUM CELL; EXTRACELLULAR FLUID; HOME DIALYSIS; HUMAN; KIDNEY TRANSPLANTATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; REVIEW; RISK FACTOR; STEM CELL;

ANEMIA; CALCINOSIS; CARDIOVASCULAR DISEASES; ENDOTHELIAL CELLS; EXTRACELLULAR FLUID; HEMODIALYSIS, HOME; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; PROGNOSIS; RISK FACTORS; STEM CELLS;

EID: 35948929876     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2007.00344.x     Document Type: Review

References (68)

1. U.S. Renal Data System : USRDS 2005 Annual Data Report Atlas of End-Stage Renal Disease in the United States. Bethesda, MD : National Institutes of Health, National Institute of Diabetes and Digestive Diseases and Kidney Diseases, 2005
2. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD : Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63 : 793 808, 2003
3. Nishizawa Y, Shoji T, Ishimura E, Kopple JD : Paradox of risk factors for cardiovascular mortality in uremia: is a higher cholesterol level better for atherosclerosis in uremia? Am J Kidney Dis 38 : S4 7, 2001
4. Fleischmann EH, Bower JD, Salahudeen AK : Risk factor paradox in hemodialysis: better nutrition as a partial explanation. ASAIO J 47 : 74 81, 2001
5. Salem MM : Hypertension in the hemodialysis population: a survey of 649 patients. Am J Kidney Dis 26 : 461 468, 1995
6. Agarwal R, Nissenson AR, Batlle D, et al. : Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 115 : 291 297, 2003
7. Baigent C, Landray M, Leaper C, et al. : First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 45 : 473 484, 2005
8. Diepeveen SHA, Verhoeven GWHE, Van Der Palen J, et al. : Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial. J Intern Med 257 : 438 445, 2005
9. Harris KPG, Wheeler DC, Chong CC : A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD. Kidney Int 61 : 1469 1474, 2002
10. Lins RL, Matthys KE, Billiouw JM, et al. : Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study. Clin Nephrol 62 : 287 294, 2004
11. Saltissi D, Morgan C, Rigby R, et al. : Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 39 : 283 290, 2002
12. Walker R, Sutherland W, Walker H, et al. : Effect of treatment with simvastatin on serum cholestryl ester transfer in patients on dialysis. Nephrol Dial Transplant 12 : 87 92, 1997
13. Wanner C, Krane V, Marz W, et al. : Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353 : 238 248, 2005
14. Wrone EM, Hornberger JM, Zehnder JL, et al. : Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 15 : 420 426, 2004
15. Lowrie EG, Laird NM, Parker TF, et al. : Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study. N Engl J Med 305 : 1176 1181, 1981
16. Eknoyan G, Beck GJ, Cheung AK, et al. : Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347 : 2010 2019, 2002
17. Paniagua R, Amato D, Vonesh E, et al. : Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13 : 1307 1320, 2002
18. Kalantar-Zadeh K, Stenvinkel P, Bross R, et al. : Kidney insufficiency and nutrient-based modulation of inflammation. Curr Opin Clin Nutr Metab Care 8 : 388 396, 2005
19. Himmelfarb J, Stenvinkel P, Ikizler TA, et al. : The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62 : 1524 1538, 2002
20. Stenvinkel P, Pecoits-Filho R, Lindholm B : Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 14 : 1927 1939, 2003
21. Prichard S : ADEMEX and HEMO trials: where are we going? Blood Purif 21 : 42 45, 2003
22. Pierratos A, Ouwendyk M, Francoeur R, et al. : Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 9 : 859 868, 1998
23. Kooistra MP : Frequent prolonged home haemodialysis: three old concepts, one modern solution. Nephrol Dial Transplant 18 : 16 18, 2003
24. Chan CT : Cardiovascular effects of frequent intensive hemodialysis. Semin Dial 17 : 99 103, 2004
25. Woods JD, Port FK, Orzol S, et al. : Clinical and biochemical correlates of starting daily hemodialysis. Kidney Int 55 : 2467 2476, 1999
26. Chan CT, Floras JS, Miller JA, et al. : Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 61 : 2235 2239, 2002
27. Chan C, Floras JS, Miller JA, et al. : Improvement in ejection fraction by nocturnal haemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant 17 : 1518 1521, 2002
28. Friedman AN, Bostom AG, Levey AS, et al. : Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis. J Am Soc Nephrol 13 : 265 268, 2002
29. Bugeja AL, Chan CT : Improvement in lipid profile by nocturnal hemodialysis in patients with end-stage renal disease. ASAIO J 50 : 328 331, 2004
30. Bergman A, Fenton SSA, Richardson RMA, et al. : Reduction in hospitalization with nocturnal hemodialysis. J Am Soc Nephrol 15 : 188A, 2004
31. Kjellstrand C, Buoncristiani U, Sibai-Galland R, et al. : Survival in 415 patients treated by short daily hemodialysis SDHD for 1006 patient years in. Hemodial Int 10 : 118, 2006
32. London GM : Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 16 : 85 94, 2003
33. Levin A, Thompson C, Ethier J, et al. : Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 34 : 125 134, 1999
34. Foley R, Parfrey P, Harnett J, et al. : The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28 : 53 61, 1996
35. Macdougall IC, Cooper AC : Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17 : 39 43, 2002
36. Horl WH, Jacobs C, Macdougall IC, et al. : European best practice guidelines 14-16 inadequate response to epoetin. Nephrol Dial Transplant 15 : 43 50, 2000
37. Movilli E, Carlo Cancarini G, Zani R, et al. : Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant 16 : 111 114, 2001
38. Ifudu O, Feldman J, Friedman EA : The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 334 : 420 425, 1996
39. Gunnell J, Yeun J, Depner T, et al. : Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33 : 63 72, 1999
40. Barany P : Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant 16 : 224 227, 2001
41. Schwartz DI, Pierratos A, Richardson RM, et al. : Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease. Clin Nephrol 63 : 202 208, 2005
42. Yuen D, Richardson RM, Fenton SS, et al. : Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness. ASAIO J 51 : 236 241, 2005
43. Urena P, Eckardt KU, Sarfati E, et al. : Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: effect of parathyroidectomy. Nephron 59 : 384 393, 1991
44. Washio M, Iseki K, Onoyama K, et al. : Elevation of serum erythropoietin after subtotal parathyroidectomy in chronic haemodialysis patients. Nephrol Dial Transplant 7 : 121 124, 1992
45. Rao DS, Shih MS, Mohini R : Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 328 : 171 175, 1993
46. Brancaccio D, Cozzolino M, Gallieni M : Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach. J Am Soc Nephrol 15 : S21 24, 2004
47. Mucsi I, Hercz G, Uldall R, et al. : Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 53 : 1399 1404, 1998
48. Yuen D, Pierratos A, Richardson RM, et al. : The natural history of coronary calcification progression in a cohort of nocturnal haemodialysis patients. Nephrol Dial Transplant 21 : 1407 1412, 2006
49. Nadra I, Mason JC, Philippidis P, et al. : Proinflammatory activation of macrophages by basic calcium phosphate crystals via protein kinase C and MAP kinase pathways: a vicious cycle of inflammation and arterial calcification? Circ Res 96 : 1248 1256, 2005
50. Tintut Y, Patel J, Parhami F, et al. : Tumor necrosis factor-{alpha} promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 102 : 2636 2642, 2000
51. Giachelli CM, Speer MY, Li X, et al. : Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res 96 : 717 722, 2005
52. Moe SM, Chen NX : Pathophysiology of vascular calcification in chronic kidney disease. Circ Res 95 : 560 567, 2004
53. Yuen D, Pierratos A, Richardson RM, Chan CT : The natural history of coronary calcification progression in a cohort of nocturnal haemodialysis patients. Nephrol Dial Transplant 21 : 1407 1412, 2006
54. Szmitko PE, Fedak PWM, Weisel RD, et al. : Endothelial progenitor cells: new hope for a broken heart. Circulation 107 : 3093 3100, 2003
55. Hill JM, Zalos G, Halcox JPJ, et al. : Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 : 593 600, 2003
56. Vasa M, Fichtlscherer S, Aicher A, et al. : Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89 : 1e 7, 2001
57. Verma S, Kuliszewski MA, Li S-H, et al. : C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between c-reactive protein and cardiovascular disease. Circulation 109 : 2058 2067, 2004
58. Choi J-H, Kim KL, Huh W, et al. : Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 24 : 1246 1252, 2004
59. Chan CT, Li SH, Verma S : Nocturnal hemodialysis is associated with restoration of impaired endothelial progenitor cell biology in end-stage renal disease. Am J Physiol Renal Physiol 289 : F679 684, 2005
60. Hanly PJ, Pierratos A : Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 344 : 102 107, 2001
61. Chan CT, Hanly P, Gabor J, et al. : Impact of nocturnal hemodialysis on the variability of heart rate and duration of hypoxemia during sleep. Kidney Int 65 : 661 665, 2004
62. Chan CT, Jain V, Picton P, et al. : Nocturnal hemodialysis increases arterial baroreflex sensitivity and compliance and normalizes blood pressure of hypertensive patients with end-stage renal disease. Kidney Int 68 : 338 344, 2005
63. Chan CT, Harvey PJ, Picton P, et al. : Short-term blood pressure, noradrenergic, and vascular effects of nocturnal home hemodialysis. Hypertension 42 : 925 931, 2003
64. Kasiske BL, Chakkera HA, Roel J : Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11 : 1735 1743, 2000
65. Aakhus S, Dahl K, Wideroe T : Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 14 : 648 654, 1999
66. Pelletier SJ, Maraschio MA, Schaubel DE, et al. : Survival benefit of kidney and liver transplantation for obese patients on the waiting list. Clin Transpl 6 : 77 88, 2003
67. Fazelzadeh A, Mehdizadeh A, Ostovan MA, et al. : Incidence of cardiovascular risk factors and complications before and after kidney transplantation. Transplant Proc 38 : 506 508, 2006
68. Massy ZA : Cardiovascular risk factors in kidney transplantation. Curr Opin Urol 11 : 139 142, 2001